Sarepta Therapeutics,, Inc. Common Stock

SRPT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
SRPT Income Statement
SRPT Balance Sheet
SRPT Cash Flow
Congress Trading

Recent trades of SRPT by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul. 14, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 13, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Apr. 10, 2023
Daniel S. Goldman House / D Purchase $15,001 - $50,000 Mar. 06, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Mar. 06, 2023
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jan. 31, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 06, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Sep. 14, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jun. 10, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 13, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Oct. 11, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Oct. 10, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Apr. 09, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar. 11, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb. 27, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb. 26, 2019
SRPT Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
SRPT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SRPT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by SRPT's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $250,000 Oct 21, 2024 Issue: Science/Technology Taxation/Internal Revenue Code Health Issues
  • $240,000 Jul 19, 2024 Issue: Science/Technology Taxation/Internal Revenue Code Health Issues
  • $240,000 Apr 19, 2024 Issue: Science/Technology Taxation/Internal Revenue Code Health Issues
  • $240,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Oct 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $220,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $160,000 Apr 18, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $180,000 Jan 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $230,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $120,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $100,000 Apr 18, 2022 Issue: Health Issues
  • $140,000 Jan 19, 2022 Issue: Health Issues
  • $140,000 Oct 19, 2021 Issue: Health Issues
  • $150,000 Jul 20, 2021 Issue: Health Issues
  • $130,000 Apr 19, 2021 Issue: Health Issues
  • $130,000 Jan 20, 2021 Issue: Health Issues
  • $80,000 Oct 19, 2020 Issue: None
  • $140,000 Jul 17, 2020 Issue: Health Issues
  • $140,000 Apr 20, 2020 Issue: Health Issues
  • $150,000 Jan 16, 2020 Issue: Health Issues
  • $150,000 Oct 31, 2019 Issue: Health Issues
  • $150,000 Sep 24, 2019 Issue: Health Issues
  • $100,000 Sep 24, 2019 Issue: Health Issues
  • $150,000 Jan 18, 2019 Issue: Health Issues
  • $130,000 Oct 22, 2018 Issue: Health Issues
  • $130,000 Jul 19, 2018 Issue: Health Issues
  • $130,000 May 23, 2018 Issue: Health Issues Budget/Appropriations Medicare/Medicaid
  • $80,000 Apr 11, 2018 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $80,000 Oct 20, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations
  • $80,000 Jul 25, 2017 Issue: Health Issues Budget/Appropriations Medicare/Medicaid
  • $80,000 Jun 06, 2017 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $80,000 Feb 16, 2017 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $80,000 Nov 23, 2016 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $80,000 Aug 03, 2016 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $110,000 Apr 20, 2016 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $110,000 Jan 20, 2016 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
  • $110,000 Nov 03, 2015 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $110,000 Jul 20, 2015 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark
  • $100,000 Apr 17, 2015 Issue: Budget/Appropriations Health Issues
  • $100,000 Feb 11, 2015 Issue: Health Issues Budget/Appropriations
  • $80,000 Oct 17, 2014 Issue: Budget/Appropriations Health Issues
  • $40,000 Jul 09, 2014 Issue: Health Issues
  • $40,000 Apr 15, 2014 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene Nov. 12, 2024
  • Patent Title: Cell-penetrating peptides for antisense delivery Nov. 12, 2024
  • Patent Title: Modified antisense oligomers for exon inclusion in spinal muscular atrophy Oct. 22, 2024
  • Patent Title: Adeno-associated virus vectors for treatment of rett syndrome Oct. 01, 2024
  • Patent Title: Exon skipping compositions for treating muscular dystrophy Mar. 19, 2024
  • Patent Title: Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy Mar. 12, 2024
  • Patent Title: Antisense-induced exon exclusion in type vii collagen Feb. 27, 2024
  • Patent Title: Oligonucleotide analogues targeting human lmna Oct. 31, 2023
  • Patent Title: Peptide oligonucleotide conjugates Aug. 22, 2023
  • Patent Title: Oligonucleotides for treating expanded repeat diseases Jun. 13, 2023
  • Patent Title: Peptide oligonucleotide conjugates Jun. 13, 2023
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy May. 09, 2023
  • Patent Title: Antisense oligomer compounds Jan. 17, 2023
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Nov. 08, 2022
  • Patent Title: Adeno-associated virus antibodies, fragments thereof and encoding polynucleotides Oct. 18, 2022
  • Patent Title: Processes for preparing phosphorodiamidate morpholino oligomers Oct. 18, 2022
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Jul. 26, 2022
  • Patent Title: Processes for preparing oligomers Jul. 12, 2022
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Jul. 12, 2022
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy May. 24, 2022
  • Patent Title: Antisense-induced exon2 inclusion in acid alpha-glucosidase Feb. 01, 2022
  • Patent Title: Compound and method for treating myotonic dystrophy Feb. 01, 2022
  • Patent Title: Peptide oligonucleotide conjugates Jan. 18, 2022
  • Patent Title: Functionally-modified oligonucleotides and subunits thereof Dec. 28, 2021
  • Patent Title: Peptide oligonucleotide conjugates Aug. 24, 2021
  • Patent Title: Dsrna molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups Jul. 27, 2021
  • Patent Title: Oligonucleotide analogues targeting human lmna Jul. 27, 2021
  • Patent Title: Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene Jul. 13, 2021
  • Patent Title: Methods and compounds for treatment of lymphocyte-related diseases and conditions Jun. 01, 2021
  • Patent Title: Antisense-induced exon exclusion in myostatin May. 25, 2021
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy May. 11, 2021
  • Patent Title: Processes for preparing phosphorodiamidate morpholino oligomers Mar. 30, 2021
  • Patent Title: Processes for preparing phosphorodiamidate morpholino oligomers Mar. 16, 2021
  • Patent Title: Compound and method for treating myotonic dystrophy Feb. 23, 2021
  • Patent Title: Exon skipping compositions for treating muscular dystrophy Feb. 02, 2021
  • Patent Title: Compositions for enhancing transport of molecules into cells Feb. 02, 2021
  • Patent Title: Modified antisense oligomers for exon inclusion in spinal muscular atrophy Feb. 02, 2021
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Jan. 12, 2021
  • Patent Title: Processes for preparing oligomers Dec. 29, 2020
  • Patent Title: Antisense-induced exon exclusion in type vii collagen Dec. 01, 2020
  • Patent Title: Oligonucleotide analogues targeting human lmna Nov. 03, 2020
  • Patent Title: Antisense molecules and methods for treating pathologies Sep. 22, 2020
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Sep. 08, 2020
  • Patent Title: Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups Sep. 01, 2020
  • Patent Title: Exon skipping oligomer conjugates for muscular dystrophy Sep. 01, 2020
  • Patent Title: Peptide oligonucleotide conjugates Jun. 09, 2020
  • Patent Title: Induced exon inclusion in spinal muscle atrophy Mar. 03, 2020
  • Patent Title: Splice-region antisense composition and method Jan. 14, 2020
  • Patent Title: Peptide oligonucleotide conjugates Nov. 26, 2019
  • Patent Title: Antisense antiviral compound and method for treating ss/rna viral infection Nov. 19, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of SRPT in WallStreetBets Daily Discussion

SRPT News

Recent insights relating to SRPT

CNBC Recommendations

Recent picks made for SRPT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SRPT

SRPT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SRPT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top